Literature DB >> 23222877

Prevalence and prognosis of unclassifiable interstitial lung disease.

Christopher J Ryerson1, Thomas H Urbania, Luca Richeldi, Joshua J Mooney, Joyce S Lee, Kirk D Jones, Brett M Elicker, Laura L Koth, Talmadge E King, Paul J Wolters, Harold R Collard.   

Abstract

The aim of this study was to determine the prevalence, characteristics and outcomes of patients with unclassifiable interstitial lung disease (ILD) and to develop a simple method of predicting disease behaviour. Unclassifiable ILD patients were identified from an ongoing longitudinal cohort. Unclassifiable ILD was diagnosed after a multidisciplinary review did not secure a specific ILD diagnosis. Clinical characteristics and outcomes were compared with idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs. Independent predictors of mortality were determined using Cox proportional-hazards analysis to identify subgroups with distinct disease behaviour. Unclassifiable ILD was diagnosed in 10% of the ILD cohort (132 out of 1370 patients). The most common reason for being unclassifiable was missing histopathological assessment due to a high risk of surgical lung biopsy. Demographic and physiological features of unclassifiable ILD were intermediate between IPF and non-IPF disease controls. Unclassifiable ILD had longer survival rates when compared to IPF on adjusted analysis (hazard ratio 0.62, p = 0.04) and similar survival compared to non-IPF ILDs (hazard ratio 1.54, p = 0.12). Independent predictors of survival in unclassifiable ILD included diffusion capacity of the lung for carbon monoxide (p = 0.001) and a radiological fibrosis score (p = 0.02). Unclassifiable ILD represents approximately 10% of ILD cases and has a heterogeneous clinical course, which can be predicted using clinical and radiological variables.

Entities:  

Mesh:

Year:  2012        PMID: 23222877     DOI: 10.1183/09031936.00131912

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  61 in total

1.  The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.

Authors:  Robert Brownell; Teng Moua; Travis S Henry; Brett M Elicker; Darin White; Eric Vittinghoff; Kirk D Jones; Anatoly Urisman; Carlos Aravena; Kerri A Johannson; Jeffrey A Golden; Talmadge E King; Paul J Wolters; Harold R Collard; Brett Ley
Journal:  Thorax       Date:  2017-01-12       Impact factor: 9.139

2.  Three Patients With Acute Pulmonary Damage Following the Use of E-Cigarettes-A Case Series.

Authors:  Hendrik Suhling; Tobias Welte; Thomas Fuehner
Journal:  Dtsch Arztebl Int       Date:  2020-03-13       Impact factor: 5.594

3.  Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore.

Authors:  Gin Tsen Chai; Teck Choon Tan; Yeong Shyan Lee; Gregory Jl Kaw; Khoon Leong Chuah; Yi Jing Lim; John Arputhan Abisheganaden; Bernard Yh Thong
Journal:  Singapore Med J       Date:  2019-07-11       Impact factor: 1.858

4.  A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Authors:  Christopher J Ryerson; Tamera J Corte; Joyce S Lee; Luca Richeldi; Simon L F Walsh; Jeffrey L Myers; Jürgen Behr; Vincent Cottin; Sonye K Danoff; Kevin R Flaherty; David J Lederer; David A Lynch; Fernando J Martinez; Ganesh Raghu; William D Travis; Zarir Udwadia; Athol U Wells; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

Review 5.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

6.  Impact of Psychological Deficits and Pain on Physical Activity of Patients with Interstitial Lung Disease.

Authors:  Seo Am Hur; Sabina A Guler; Nasreen Khalil; Pat G Camp; Jordan A Guenette; Christopher J Ryerson
Journal:  Lung       Date:  2019-06-01       Impact factor: 2.584

7.  Idiopathic pulmonary fibrosis: past, present, future-a review from Talmadge King's ATS 2016 presentation.

Authors:  S Clark Berngard; Kamyar Afshar
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

8.  Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Jonathan H Chung; Steven M Montner; Cathryn Lee; Leah J Witt; Danielle Stahlbaum; Rene S Bermea; Lena W Chen; Scully Hsu; Aliya N Husain; Imre Noth; Rekha Vij; Mary E Strek; Matthew Churpek
Journal:  Chest       Date:  2017-09-28       Impact factor: 9.410

9.  [Current classification of interstitial pulmonary diseases].

Authors:  J Vogel-Claussen; A Prasse
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

10.  Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Authors:  Ganesh Raghu; Athol U Wells; Andrew G Nicholson; Luca Richeldi; Kevin R Flaherty; Florence Le Maulf; Susanne Stowasser; Rozsa Schlenker-Herceg; David M Hansell
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.